CARE Ratings Q2 FY27 results show 20% operating income growth, 26% PAT growth and 23% EBITDA growth, led by ratings business revenue.

CARE Ratings Q2 FY27 Results: Can Profit Growth Continue?

The latest reported results indicate that CARE Ratings continued to expand both operating income and profitability in Q2 FY27. PAT growth outpaced operating income growth, while EBITDA also increased at a healthy pace. These figures point to improved earnings compared with the corresponding quarter of the previous financial year, although a fuller assessment would require expense details, margins, cash flows and management commentary.

CARE Ratings operates in the credit-rating and financial-information ecosystem. Its performance can be influenced by demand for credit ratings, debt issuance activity, growth in the financial system, regulatory requirements and its ability to expand related services. Investors should consider these business drivers alongside the quarterly numbers rather than relying on headline growth rates alone.

Revenue Growth: Ratings Business Remains the Main Contributor

CARE Ratings reported consolidated operating income of ₹164.13 crore, representing 20% growth over the corresponding quarter of the previous year. Within this total, ratings business revenue reached ₹148.51 crore, growing 21% year-on-year. Non-ratings business revenue increased 15% to ₹15.62 crore.

The ratings business therefore accounted for the larger share of the reported operating income. This makes the performance of the core ratings franchise particularly important when evaluating the company's future growth. Continued demand for credit assessments and related services could support revenue, but the pace of growth may also depend on debt-market activity, corporate borrowing and broader economic conditions.

The non-ratings business provides an additional revenue stream. Its 15% growth suggests expansion in this segment, although the supplied figures do not identify individual services or explain which activities contributed most to the increase.

Investors should also distinguish revenue growth from growth in underlying business volumes. The available figures do not specify rating mandates, new-client additions, market share or revenue contribution by individual sectors. Those details would help determine whether growth reflects a broad-based expansion or a smaller number of business drivers.

Profitability: PAT Growth Outpaces Operating Income

Consolidated PAT increased 26% year-on-year to ₹72.37 crore, exceeding the 20% growth in operating income. Consolidated EBITDA rose 23% to ₹84.61 crore. The stronger growth in PAT relative to operating income is encouraging, but the available summary does not provide enough detail to establish the exact reasons for this difference.

Possible factors that investors typically examine include operating-cost growth, employee expenses, other income, depreciation, finance costs and taxation. These components need to be checked in the full financial statements before drawing conclusions about the sustainability of earnings growth.

Using the supplied consolidated figures, EBITDA was approximately 51.6% of operating income for the quarter. This is a calculated ratio, not a separately reported company metric. Its interpretation depends on the company's EBITDA definition and the precise composition of operating income. A year-on-year comparison would be needed to determine whether operating profitability improved.

Standalone PAT reached ₹69.16 crore, up 24% year-on-year. The difference between consolidated and standalone PAT reflects the distinction between the parent company's results and the consolidated group results. The supplied summary does not provide enough information to attribute that difference to any particular subsidiary or activity.

What Investors Should Monitor Next

The next stage of analysis should focus on whether the growth seen in Q2 can continue through the second half of FY27. Investors should review the full results for operating expenses, employee costs, EBITDA margin trends, cash generation and management's outlook.

Business momentum is another important consideration. Credit-rating demand may change with corporate borrowing, bond issuance, bank lending and the wider financing environment. Growth in the non-ratings business could also become more important if it develops into a larger contributor over time.

Valuation must be considered separately from earnings growth. A company can report strong results yet deliver disappointing share-price performance if expectations were already high or the market assigns a lower valuation multiple. A meaningful valuation assessment would require the current share price, earnings per share, market capitalisation and relevant peer comparisons, none of which were included in the supplied financial highlights.

The quarterly numbers provide a positive starting point, but a complete investment decision should include both financial and business analysis. Growth rates alone do not establish whether a share is attractively valued or whether current profitability can be maintained.

Valuation and Investment View

Investor Takeaway

Derivative Pro & Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, observes that CARE Ratings' reported Q2 FY27 results demonstrate healthy year-on-year growth across operating income, EBITDA and consolidated PAT. The ratings business remains the largest reported revenue contributor, while non-ratings revenue also expanded.

The key question for investors is whether this growth can be sustained and how it translates into future margins and cash generation. The supplied results are positive on growth, but an investment decision should also consider the stock's current valuation, the complete financial statements and the company's future business outlook.

Read more market analysis at Indian-Share-Tips.com or contact 9988877963.

Related Queries on CARE Ratings Results and Share Analysis

1. What was CARE Ratings' consolidated operating income in Q2 FY27?
Consolidated operating income was ₹164.13 crore, up 20% year-on-year.

2. What was CARE Ratings' consolidated PAT in Q2 FY27?
Consolidated PAT was ₹72.37 crore, representing 26% year-on-year growth.

3. How much did consolidated EBITDA increase?
Consolidated EBITDA reached ₹84.61 crore, up 23% year-on-year.

4. Which business contributed the most revenue?
The ratings business was the larger contributor, reporting revenue of ₹148.51 crore, up 21% year-on-year.

5. How did the non-ratings business perform?
Non-ratings business revenue was ₹15.62 crore, up 15% year-on-year.

6. Do these results prove that CARE Ratings shares are undervalued?
No. The results show reported earnings growth, but determining valuation requires the current share price, earnings multiples, cash-flow data and comparison with relevant peers.

SEBI Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy or sell any security. Financial figures are based on the information supplied and have not been independently verified against the company's full financial statements. Stock-market investments are subject to market risks, including loss of capital. Please conduct your own research and consult a qualified financial adviser where appropriate. No return is guaranteed.